Vivani Medical, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vivani Medical, Inc. (VANI) on March 6, 2024, covering events occurring on March 4, 2024. The filing addresses corporate governance changes, specifically the expansion of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of a new director and does not contain financial performance data.
Material Changes
The Board of Directors expanded from five to six members. Daniel Bradbury was unanimously appointed to fill the newly created vacancy. He will serve until the 2025 annual meeting of stockholders or until earlier resignation, death, or removal. Additionally, Mr. Bradbury was appointed to the Audit Committee.
Management Commentary and Compensation
Mr. Bradbury brings significant life sciences experience, including roles as Executive Chairman of Equillium, Inc. and former CEO of Amylin Pharmaceuticals. His compensation includes:
- Board Retainer: $35,000 annually.
- Audit Committee Retainer: $10,000 annually.
There are no family relationships between Mr. Bradbury and existing officers or directors, and no special arrangements influenced his appointment.
Investor Verification Checklist
- Verify the effective date of the Board expansion and Mr. Bradbury's tenure.
- Confirm the total annual cash compensation for the new director ($45,000).
- Review the attached press release (Exhibit 99.1) for additional strategic context.
- Check subsequent filings for any changes to the Audit Committee composition.